NKTX - NASDAQ
Nkarta, Inc.
$2.72
-1.8%Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live SnapshotNkarta, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Nkarta, Inc. Balance Sheet
NKTX • NASDAQ
| Nkarta, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
39.6M | 27.9M | 31M | 37.5M | 60.8M | 96.7M | 20.6M | 7.9M | |
236.6M | 239.5M | 217.1M | 314.6M | 177.3M | 218.2M | 16.4M | 0.0 | |
276.3M | 267.4M | 248.2M | 352.1M | 238.1M | 314.9M | 37M | 7.9M | |
2M | 200K | 200K | 1.3M | 0.0 | 0.0 | 0.0 | 150K | |
0.0 | 200K | 200K | 1.3M | 0.0 | 0.0 | 0.0 | 0.0 | |
2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 150K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 117.3K | |
0.0 | 3.2M | 3.3M | 5.6M | 4.5M | 2.6M | 407.4K | 117.3K | |
4.2M | 2.5M | 1.4M | 1.6M | 3.2M | 1.3M | 66.5K | 94.4K | |
282.5M | 273.3M | 253.1M | 360.7M | 245.8M | 318.8M | 37.5M | 8.2M | |
NON-CURRENT ASSETS | ||||||||
101.2M | 110.7M | 119.3M | 107.7M | 24.5M | 17.9M | 10.2M | 1.3M | |
16.1M | 110.4M | 2.7M | 2.7M | 0.0 | 0.0 | 268.5K | 89.8K | |
4.4M | 6.8M | 3.8M | 1.9M | 3.6M | 960K | 455.1K | 0.0 | |
121.7M | 227.9M | 125.8M | 112.3M | 28.1M | 18.8M | 10.9M | 1.4M | |
404.2M | 501.2M | 378.9M | 472.9M | 273.9M | 337.7M | 48.4M | 9.6M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
2.1M | 638K | 3.7M | 1.8M | 1.1M | 1.2M | 1.9M | 375.3K | |
2.1M | 638K | 3.7M | 1.8M | 1.1M | 1.2M | 1.9M | 367.2K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.2K | |
0.0 | 12M | 6.9M | 6.7M | 9.3M | 6.1M | 3M | 1.3M | |
6.9M | 0.0 | 0.0 | 4.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 6.1M | 6.1M | 0.0 | 2.5M | 1.4M | 1.5M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.1K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.7M | 0.0 | |
13.3M | 254K | 6.7M | 9.3M | 96K | 117K | -857.4K | 408.4K | |
22.3M | 18.9M | 23.3M | 22M | 12.9M | 8.8M | 8.2M | 2.1M | |
NON-CURRENT LIABILITIES | ||||||||
87K | 87K | 0.0 | 0.0 | 18K | 82K | 59.9M | 12.9M | |
69.6M | 74.3M | 82.3M | 78.7M | 10M | 7.6M | 65.7M | 12.9M | |
69.5M | 80.3M | 88.3M | 78.7M | 12.5M | 8.9M | 7.3M | 0.0 | |
91.9M | 93.2M | 105.6M | 100.7M | 22.9M | 16.4M | 73.9M | 15M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 59.8K | 12.7M | |
7K | 7K | 5K | 5K | 3K | 3K | 160.0 | 123.0 | |
960.2M | 951.5M | 708.7M | 690.8M | 455.2M | 439.2M | 1.2M | 187.5K | |
-648.3M | -544.2M | -435.4M | -317.9M | -204.1M | -118M | -26.7M | -5.6M | |
407K | 674K | 8K | -679K | -150K | 3K | -2.1K | -244.8K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -59.1K | 245.1K | |
312.3M | 408M | 273.3M | 372.2M | 251M | 321.2M | -25.5M | -5.4M | |
312.3M | 408M | 273.3M | 372.2M | 251M | 321.2M | -25.5M | -5.4M | |
SUMMARY | ||||||||
404.2M | 501.2M | 378.9M | 472.9M | 273.9M | 337.7M | 48.4M | 9.6M | |
252.8M | 349.9M | 219.9M | 317.4M | 177.3M | 218.2M | 16.4M | 89.8K | |
76.4M | 80.3M | 88.3M | 82.9M | 12.5M | 8.9M | 7.3M | 12.7M | |
36.8M | 52.4M | 57.3M | 45.4M | -48.4M | -87.8M | -13.3M | 4.8M | |
71,024,512 | 71,024,512 | 71,024,512 | 71,024,512 | 71,024,512 | 71,024,512 | 71,024,512 | 71,024,512 |
SEC Filings
NKTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 25, 2026 | 2026 | |
S-3 S-3 N/A | March 25, 2026 | March 25, 2026 | ||
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your NKTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.